NYSE · ENOV
Industrials · Industrial - Machinery
$24.83
Down-$0.42 (-1.66%)
Updated Aug 28, 2026, 6:20 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ENOV closed at $24.83 after 21 trading sessions, down 15.26% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $25.13 | $25.40 | $24.78 | $24.83 | 486.36K |
| Aug 26, 2026 | $25.30 | $25.43 | $24.635 | $25.25 | 553.56K |
| Aug 25, 2026 | $25.23 | $25.65 | $24.68 | $25.58 | 565.37K |
| Aug 24, 2026 | $26.28 | $26.93 | $24.98 | $25.21 | 625.29K |
| Aug 21, 2026 | $26.19 | $26.41 | $25.50 | $26.06 | 611K |
| Aug 20, 2026 | $26.20 | $26.88 | $25.935 | $26.18 | 657.56K |
| Aug 19, 2026 | $25.69 | $27.46 | $25.69 | $26.50 | 748.36K |
| Aug 18, 2026 | $25.14 | $26.11 | $24.89 | $25.64 | 807.5K |
| Aug 17, 2026 | $25.47 | $25.755 | $24.50 | $24.74 | 1.09M |
| Aug 14, 2026 | $25.79 | $26.44 | $25.79 | $26.06 | 867.53K |
| Aug 13, 2026 | $24.89 | $25.70 | $24.225 | $25.66 | 1.02M |
| Aug 12, 2026 | $24.23 | $24.72 | $23.625 | $24.69 | 1.14M |
| Aug 11, 2026 | $24.39 | $25.16 | $24.23 | $24.60 | 887.61K |
| Aug 10, 2026 | $26.35 | $26.59 | $24.18 | $24.24 | 1.76M |
| Aug 7, 2026 | $25.72 | $26.82 | $24.65 | $26.61 | 2.06M |
| Aug 6, 2026 | $28.86 | $28.86 | $25.465 | $26.31 | 3.13M |
| Aug 5, 2026 | $31.02 | $31.10 | $30.00 | $30.18 | 1.5M |
| Aug 4, 2026 | $31.06 | $31.665 | $30.50 | $30.86 | 1.37M |
| Aug 3, 2026 | $29.93 | $31.52 | $29.93 | $31.42 | 1.59M |
| Jul 31, 2026 | $28.79 | $29.31 | $28.2158 | $29.15 | 770.28K |
| Jul 30, 2026 | $29.83 | $30.48 | $29.24 | $29.30 | 869.47K |
The latest Smart Investors Daily articles mentioning ENOV.
ENOV research
Company profile and research snapshot.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Buy | — |
| Aug 7, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jul 9, 2026 | BMO Capital | Outperform | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Aug 21, 2026
Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Click to read.
SeekingAlpha · Aug 20, 2026
Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Learn more about ENOV stock here.
Benzinga · Aug 17, 2026
Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $50 to $45.
Yahoo · Aug 8, 2026
Enovis (NYSE:ENOV) reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Performance & Recovery segment. Management said the company’s results reflected improved commercial ex
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENOV.
